The malignant ascites pipeline possesses only two drugs in mid-stage developments to be approved in the near future. The major key players include Clover Biopharmaceuticals and Wuhan YZY Biopharma which hold the potential to create a significant positive shift in the malignant ascites market size.
LAS VEGAS, April 29, 2024 /PRNewswire/ -- DelveInsight's Malignant Ascites Market Insights report includes a comprehensive understanding of current treatment practices, malignant ascites emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Malignant Ascites Market Report
- According to DelveInsight's analysis, the market size for malignant ascites reached USD 1.9 billion in 2020 across the 7MM, which is anticipated to rise to USD 2.3 billion by 2034.
- In 2020, the total incident cases of malignant ascites-associated cancers were ~1.6 million in the 7MM.
- Leading malignant ascites companies such as LINDIS BIOTECH, WUHAN YZY BIOPHARMA CO., LTD., CLOVER BIOPHARMACEUTICALS, BINHUI BIOPHARMACEUTICAL, PHARMACYTE BIOTECH INC., and others are developing novel malignant ascites drugs that can be available in the malignant ascites market in the coming years.
- The promising malignant ascites therapies in the pipeline include CATUMAXOMAB, M 701, SCB-313, VAK, and CYPSCAPS PLUS IFOSFAMIDE, among others.
- Wuhan YZY Biopharma's M701 is the first and only EpCAM × CD3 BsAb that has entered into a Phase II clinical trial for the treatment of M701 globally.
- Even with the new therapies coming in the market, still the mainstay treatment for Malignant Ascites will remain chemotherapy over the years. Out of the novel treatments, the highest revenue is expected to be generated by CATUMAXOMAB with 10.54% of share of the total market in 2034, followed by KM-CART with 5.07% and OK-432 with 2.21% of market share, respectively.
Discover which therapies are expected to grab the major malignant ascites market share @ Malignant Ascites Market Report
Malignant Ascites Overview
Malignant ascites is a pathological condition stemming from various primary abdominal and non-abdominal cancers. It stands as a significant source of illness, presenting numerous complexities and treatment obstacles. It serves as an indicator of peritoneal carcinomatosis, denoting the presence of cancerous cells within the peritoneal cavity. Carcinomatosis-causing tumors are frequently secondary malignancies affecting the peritoneal surface, such as those from ovarian, colorectal, pancreatic, and uterine origins; as well as extraperitoneal tumors originating from lymphoma, lung, and breast cancers, alongside smaller proportion of unidentified primary tumors.
The origins of fluid accumulation within the abdomen are diverse and may include cirrhosis, congestive heart failure, nephrosis, pancreatitis, peritonitis, primary malignancies, or liver metastases. Differentiating between benign and malignant ascites solely through physical examination or radiographic methods is not feasible. Invasive procedures are required to distinguish between the two types. Ascitic fluid analysis through abdominal paracentesis can typically identify malignant causes of ascite production; however, laparoscopic tissue sampling might be necessary in certain cases.
Malignant Ascites Epidemiology Segmentation
The malignant ascites epidemiology section provides insights into the historical and current malignant ascites patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The malignant ascites market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Incident Cases of Ascites in Selected Indications (Ovarian, Colorectal, Gastric, and Others)
- Incident Cases of Malignant Ascites in Selected Indications
- Total Treated Cases of Malignant Ascites
Malignant Ascites Treatment Market
The available treatments for malignant ascites consist of various strategies designed to ease symptoms and enhance quality of life. These methods include draining fluids through paracentesis, using chemotherapy to combat cancer cells and lessen ascite formation, employing targeted therapy tailored to particular cancer types, opting for surgical procedures like tumor removal or shunt insertion, and incorporating supportive measures such as diuretics and nutritional assistance. The selection of treatment is determined by factors such as the specific cancer type and the severity of symptoms, with the main objective being the management of symptoms and the improvement of overall well-being.
Malignant ascite treatments aimed at causing a reduction in malignant ascites mainly consist of systemic chemotherapy, targeted therapy, or surgical procedures designed to decrease or remove the cancerous tumors accountable for the development of ascites. These methods focus on the fundamental cause of ascites by dealing with the underlying cancer, intending to slow down the advancement of the disease and enhance the outcomes for the patient.
With just two accepted treatments, OK-432 and KM-CART, available in Japan, many patients are left with only palliative care, which often falls short of addressing their needs. Various methods exist to relieve symptoms linked with malignant ascites. However, due to a lack of understanding of ascites' natural progression, there is limited data on these approaches and their impact on quality of life. Assessing the effectiveness of current treatments is challenging. Common traditional methods for handling malignant ascites encompass sodium-restricted diets, diuretic treatment, repeated paracentesis, and peritoneovenous shunting.
To know more about malignant ascites treatment guidelines, visit @ Malignant Ascites Management
Malignant Ascites Pipeline Therapies and Key Companies
- CATUMAXOMAB: LINDIS BIOTECH
- M 701: WUHAN YZY BIOPHARMA CO., LTD.
- SCB-313: CLOVER BIOPHARMACEUTICALS
- VAK: BINHUI BIOPHARMACEUTICAL
- CYPSCAPS PLUS IFOSFAMIDE: PHARMACYTE BIOTECH INC.
Learn more about the FDA-approved drugs for malignant ascites @ Drugs for Malignant Ascites Treatment
Malignant Ascites Market Dynamics
The dynamics of the malignant ascites market are expected to change in the coming years. SCB-313 utilizes distinctive, patented protein trimerization technology to precisely target and activate the triple-dependent mechanism of tumor cell apoptosis, fostering collaboration among oncologists, surgeons, researchers, and other healthcare professionals to develop effective management strategies, identification of novel therapeutic targets through advanced molecular analyses, and an emphasis on patient-centered care and improved symptom management to enhance the overall quality of life for patients with malignant ascites.
Furthermore, many potential therapies are being investigated for the treatment of malignant ascites, and it is safe to predict that the treatment space will significantly impact the malignant ascites market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the malignant ascites market in the 7MM.
However several factors may impede the growth of the malignant ascites market. Tackling malignant ascites poses ongoing difficulties in clinical management, with the current focus primarily on alleviating symptoms rather than achieving a definitive cure, due to the absence of universally accepted treatment protocols stemming from limited evidence and patient heterogeneity; consequently, malignant ascites also presents research obstacles, with only a few attempts made to develop medications for the condition, and the potential hindrance of access to emerging therapies once approved by the availability of off-label therapies.
Moreover, malignant ascites treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the malignant ascites market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the malignant ascites market growth.
Malignant Ascites Market Report Metrics | Details |
Study Period | 2020-2034 |
Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
Malignant Ascites Market CAGR | 1.2 % |
Malignant Ascites Market Size in 2020 | USD 1.9 Billion |
Key Malignant Ascites Companies | LINDIS BIOTECH, WUHAN YZY BIOPHARMA CO., LTD., CLOVER BIOPHARMACEUTICALS, BINHUI BIOPHARMACEUTICAL, PHARMACYTE BIOTECH INC., and others |
Key Pipeline Malignant Ascites Therapies | CATUMAXOMAB, M 701, SCB-313, VAK, CYPSCAPS PLUS IFOSFAMIDE, and others |
Scope of the Malignant Ascites Market Report
- Therapeutic Assessment: Malignant Ascites current marketed and emerging therapies
- Malignant Ascites Market Dynamics: Key Market Forecast Assumptions of Emerging Malignant Ascites Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Malignant Ascites Market Access and Reimbursement
Discover more about malignant ascites drugs in development @ Malignant Ascites Clinical Trials
Table of Contents
1 | KEY INSIGHTS |
2 | REPORT INTRODUCTION |
3 | EXECUTIVE SUMMARY OF MALIGNANT ASCITES |
4 | MALIGNANT ASCITES MARKET OVERVIEW AT A GLANCE |
4.1 | MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2020 IN THE 7MM |
4.2 | MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2034 IN THE 7MM |
5 | KEY EVENTS |
6 | MALIGNANT ASCITES: DISEASE BACKGROUND AND OVERVIEW |
6.1 | INTRODUCTION |
6.2 | SIGN AND SYMPTOMS |
6.3 | PATHOPHYSIOLOGY |
6.3.1 | Peritoneal Physiology |
6.3.2 | Pathophysiology of Malignant Ascites |
6.4 | DIAGNOSIS |
6.5 | TREATMENT MANAGEMENT |
6.5.1 | Paracentesis |
6.5.2 | Peritoneovenous Shunts |
6.5.3 | Diuretics |
6.5.4 | Drainage Catheters |
7 | EPIDEMIOLOGY AND PATIENT POPULATION |
7.1 | KEY FINDINGS |
7.2 | ASSUMPTIONS AND RATIONALE |
7.3 | TOTAL INCIDENT CASES OF MALIGNANT ASCITES ASSOCIATED CANCERS IN THE 7MM |
7.4 | TOTAL PATIENT POOL OF MALIGNANT ASCITES IN THE 7MM |
7.5 | THE UNITED STATES |
7.5.1 | Total Incident Cases of Malignant Ascites Associated Cancers in the US |
7.5.2 | Total Patient Pool of Malignant Ascites in the US |
7.6 | EU4 AND THE UK |
7.6.1 | Total Incident Cases of Malignant Ascites Associated Cancers in EU4 and the UK |
7.6.2 | Total Patient Pool of Malignant Ascites in EU4 and the UK |
7.7 | JAPAN |
7.7.1 | Total Incident Cases of Malignant Ascites Associated Cancers in Japan |
7.7.2 | Total Patient Pool of Malignant Ascites in Japan |
8 | PATIENT JOURNEY |
9 | MARKETED DRUGS |
9.1 | OK-432: ROCHE |
9.1.1 | Product Description |
9.1.2 | Regulatory Milestones |
9.1.3 | Others Developmental Activities |
9.1.4 | Safety and Efficacy |
9.1.5 | Product Profile |
9.2 | KM-CART: ASAHI KASEI MEDICAL CO. LTD. |
9.2.1 | Product Description |
9.2.2 | Regulatory Milestones |
9.2.3 | Safety and Efficacy |
9.2.4 | Product Profile |
10 | EMERGING DRUGS |
10.1 | KEY COMPETITORS |
10.2 | CATUMAXOMAB: LINDIS BIOTECH |
10.2.1 | Product Description |
10.2.2 | Other Developmental Activities |
10.2.3 | Clinical Development |
10.2.3.1 | Clinical Trials Information |
10.2.4 | Safety and Efficacy |
10.3 | M 701: WUHAN YZY BIOPHARMA CO., LTD. |
10.3.1 | Product Description |
10.3.2 | Other Developmental Activities |
10.3.3 | Clinical Development |
10.3.3.1 | Clinical Trials Information |
10.3.4 | Safety and Efficacy |
10.4 | SCB-313: CLOVER BIOPHARMACEUTICALS |
10.4.1 | Product Description |
10.4.2 | Other Developmental Activities |
10.4.3 | Clinical Development |
10.4.3.1 | Clinical Trials Information |
10.4.4 | Safety and Efficacy |
10.5 | VAK: BINHUI BIOPHARMACEUTICAL |
10.5.1 | Product Description |
10.5.2 | Clinical Development |
10.5.2.1 | Clinical Trials Information |
10.6 | CYPSCAPS PLUS IFOSFAMIDE: PHARMACYTE BIOTECH INC. |
10.6.1 | Product Description |
10.6.2 | Other Developmental Activities |
10.6.3 | Safety and Efficacy |
11 | MALIGNANT ASCITES: MARKET ANALYSIS |
11.1 | KEY FINDINGS |
11.2 | MARKET OUTLOOK |
11.3 | TOTAL MARKET SIZE OF MALIGNANT ASCITES IN THE 7MM |
11.4 | UNITED STATES MARKET SIZE |
11.4.1 | Total Market Size of Malignant Ascites in the United States |
11.4.2 | Market Size of Malignant Ascites by Therapies in the United States |
11.5 | EU4 AND THE UK MARKET SIZE |
11.5.1 | Total Market Size of Malignant Ascites in EU4 and the UK |
11.5.2 | Market Size of Malignant Ascites by Therapies in EU4 and the UK |
11.6 | JAPAN MARKET SIZE |
11.6.1 | Total Market Size of Malignant Ascites in Japan |
11.6.2 | Market Size of Malignant Ascites by Therapies in Japan |
12 | UNMET NEEDS |
13 | SWOT ANALYSIS |
14 | KOL VIEWS |
15 | MARKET ACCESS AND REIMBURSEMENT |
15.1 | UNITED STATES |
15.1.1 | Center for Medicare & Medicaid Services (CMS) |
15.1.2 | Zero Dollar Copay (ZDC) |
15.2 | EU4 AND THE UK |
15.2.1 | Germany |
15.2.2 | France |
15.2.3 | Italy |
15.2.4 | Spain |
15.2.5 | United Kingdom |
15.3 | JAPAN |
15.3.1 | MHLW |
16 | APPENDIX |
16.1 | BIBLIOGRAPHY |
16.2 | REPORT METHODOLOGY |
17 | DELVEINSIGHT CAPABILITIES |
18 | DISCLAIMER |
19 | ABOUT DELVEINSIGHT |
Related Reports
Malignant Ascites Pipeline
Malignant Ascites Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant ascites companies, including Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others.
Malignant Ascites Epidemiology Forecast
Malignant Ascites Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted malignant ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ascites Market
Ascites Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ascites companies, including Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, among others.
Ascites Pipeline
Ascites Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ascites companies, including Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/malignant-ascites-market-to-observe-growth-at-a-cagr-of-1-2-by-2034--delveinsight-302129901.html
